Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

5G Enterprise Market Projected to Reach $115.81 billion by 2030 – Exclusive Report by 360iResearch

Published

on

5g-enterprise-market-projected-to-reach-$115.81-billion-by-2030-–-exclusive-report-by-360iresearch

PUNE, India, May 2, 2024 /PRNewswire/ — The report titled “5G Enterprise Market by Equipment (Distributed Antenna System, Radio Node, Service Node), Organization Size (Large Enterprises, SMEs), End User – Global Forecast 2024-2030” is now available on 360iResearch.com’s offering, presents an analysis indicating that the market projected to grow from a size of $17.30 billion in 2023 to reach $115.81 billion by 2030, at a CAGR of 31.20% over the forecast period.

 
“The Pivotal Role of 5G Technology in Enterprise Evolution”
The advent of 5G technology marks a transformative era for businesses worldwide, offering exceptional speed, reduced latency, and enhanced connectivity that promise to elevate operational efficiency and digital innovation across various sectors. From enabling precise real-time monitoring and predictive maintenance in manufacturing to advancing telemedicine and seamless data collaborations in healthcare, 5G stands as a cornerstone for future advancements. Its pivotal role is revolutionizing transportation by supporting autonomous vehicles and smart infrastructure, significantly elevating safety and efficiency. The surge in 5G enterprise adoption is fueled by the growing need for robust and swift network connections to accommodate an increasing array of Internet of Things (IoT) devices and applications. Challenges include the substantial upfront costs associated with 5G infrastructure and concerns over data security. The potential for 5G to spur innovation is immense, mainly through the development of 5G-as-a-Service (5GaaS) and its synergy with cutting-edge technologies such as edge computing and artificial intelligence. Regionally, North America is major in adoption, supported by significant telecom investments, while the European Union’s concerted efforts bolster 5G integration across industries. The Middle East’s ambitions to become a significant region globally in 5G through smart city and industrial automation investments distinguish it. In contrast, the APAC region’s rapid growth is supported by early adoption and extensive government support, particularly in South Korea, China, and Japan. Thus, 5G is set to redefine enterprise operations, driving innovation and enabling smart solutions globally, heralding a new chapter in digital transformation for industries worldwide.
Download Sample Report @ https://www.360iresearch.com/library/intelligence/5g-enterprise
“5G’s Role in Advancing Industry 4.0 and Digital Innovations”
In today’s fast-evolving digital age, the seamless integration of cutting-edge technologies such as artificial intelligence (AI), the Internet of Things (IoT), and blockchain into everyday business operations is becoming increasingly crucial. This integration is driving a significant surge in the need for uninterrupted, high-speed network coverage across various sectors. As technologies become more affordable and their performance enhanced, their adoption in both private and public sectors is witnessing a remarkable increase, paving the way for innovative payment solutions and digital currencies. This transformation reshapes diverse commercial landscapes, including entertainment, journalism, advertising, and retail. Consequently, the demand for 5G connectivity is escalating, recognized for its capability to deliver speeds of 15 to 20 Gbps, connect a vast array of devices, and facilitate the creation of virtual networks tailored to specific needs. Moreover, as Industry 4.0 propels manufacturing into the digital era with its emphasis on automation and digital technologies, the role of 5G in supporting these advancements becomes indispensable. By enabling faster connectivity for AI, data analytics, IoT, blockchain, and machine learning applications, 5G is at the forefront of improving operational efficiency and flexibility in the manufacturing sector, setting the stage for the exponential growth of the 5G enterprise market.
“The Integral Role of Radio Nodes, DAS, and Service Nodes in Enhancing 5G Networks”
In the rapidly evolving world of 5G networks, the harmonious functioning of radio nodes, distributed antenna systems (DAS), and service nodes plays a pivotal role in ensuring uninterrupted, high-speed connectivity across diverse environments. Radio nodes, vital for facilitating direct communication between devices, including smartphones and tablets, ensure the seamless execution of critical radio functions such as modulation and demodulation. They shine especially in areas where a robust, reliable connection is paramount, catering to the needs of densely populated zones. DAS is used in complexes such as stadiums and large buildings, working behind the scenes to boost wireless coverage through a network of strategically placed antenna nodes. This ensures that every corner is connected, enhancing user experience in challenging architectural layouts. Meanwhile, service nodes are the backbone of network management, orchestrating essential functions, including user authentication and mobility management, enabling smooth delivery of services throughout the 5G ecosystem. These components overcome physical and technological hurdles and lay down the infrastructure critical for delivering the next generation of wireless connectivity.
Request Analyst Support @ https://www.360iresearch.com/library/intelligence/5g-enterprise
“Telefonaktiebolaget LM Ericsson at the Forefront of 5G Enterprise Market with a Strong 16.19% Market Share”
The key players in the 5G Enterprise Market include Huawei Technologies Co., Ltd., Deutsche Telekom AG, Nokia Corporation, Telefonaktiebolaget LM Ericsson, AT&T Inc., and others. These prominent players focus on strategies such as expansions, acquisitions, joint ventures, and developing new products to strengthen their market positions.
“Introducing ThinkMi: Revolutionizing Market Intelligence with AI-Powered Insights for the 5G Enterprise Market”
We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the 5G Enterprise Market. ThinkMi stands out as your premier market intelligence partner, delivering unparalleled insights with the power of artificial intelligence. Whether deciphering market trends or offering actionable intelligence, ThinkMi is engineered to provide precise, relevant answers to your most critical business questions. This revolutionary tool is more than just an information source; it’s a strategic asset that empowers your decision-making with up-to-the-minute data, ensuring you stay ahead in the fiercely competitive 5G Enterprise Market. Embrace the future of market analysis with ThinkMi, where informed decisions lead to remarkable growth.
Ask Question to ThinkMi @ https://app.360iresearch.com/library/intelligence/5g-enterprise
“Dive into the 5G Enterprise Market Landscape: Explore 181 Pages of Insights, 298 Tables, and 22 Figures”
PrefaceResearch MethodologyExecutive SummaryMarket OverviewMarket Insights5G Enterprise Market, by Equipment5G Enterprise Market, by Organization Size5G Enterprise Market, by End UserAmericas 5G Enterprise MarketAsia-Pacific 5G Enterprise MarketEurope, Middle East & Africa 5G Enterprise MarketCompetitive LandscapeCompetitive PortfolioInquire Before Buying @ https://www.360iresearch.com/library/intelligence/5g-enterprise
Related Reports:
5G Non-Terrestrial Network Market – Global Forecast 2024-20305G in Defense Market – Global Forecast 2024-20305G Satellite Communication Market – Global Forecast 2024-2030About 360iResearch
Founded in 2017, 360iResearch is a market research and business consulting company headquartered in India, with clients and focus markets spanning the globe.
We are a dynamic, nimble company that believes in carving ambitious, purposeful goals and achieving them with the backing of our greatest asset — our people.
Quick on our feet, we have our ear to the ground when it comes to market intelligence and volatility. Our market intelligence is diligent, real-time and tailored to your needs, and arms you with all the insight that empowers strategic decision-making.
Our clientele encompasses about 80% of the Fortune Global 500, and leading consulting and research companies and academic institutions that rely on our expertise in compiling data in niche markets. Our meta-insights are intelligent, impactful and infinite, and translate into actionable data that support your quest for enhanced profitability, tapping into niche markets, and exploring new revenue opportunities.
Contact 360iResearchMr. Ketan Rohom360iResearch Private Limited,Office No. 519, Nyati Empress,Opposite Phoenix Market City,Vimannagar, Pune, Maharashtra,India – 411014.Email: [email protected]: +1-530-264-8485India: +91-922-607-7550
To learn more, visit 360iresearch.com or follow us on LinkedIn, Twitter, and Facebook.
Logo: https://mma.prnewswire.com/media/2359256/360iResearch_Logo.jpg
 

View original content:https://www.prnewswire.co.uk/news-releases/5g-enterprise-market-projected-to-reach-115-81-billion-by-2030—exclusive-report-by-360iresearch-302134462.html

Continue Reading
Advertisement
Stake.com

Artificial Intelligence

ActiveOps becomes Official Analytics Partner to Great Britain 7s Rugby team

Published

on

activeops-becomes-official-analytics-partner-to-great-britain-7s-rugby-team

Highlighting the necessity of data-driven decision-making as a central tenet to both athletes on the pitch and employees in the workforceAgreement enables ActiveOps to provide analytics expertise to support the teams growth and performance plans globallyGlobal deal covers both Men and Women’s GB7s teams for the 2024/25 HSBC SVNS SeasonLONDON, May 30, 2024 /PRNewswire/ — ActiveOps, leaders in providing AI-powered Decision Intelligence software for service operations, is extremely proud to announce a strategic and global partnership with Great Britain men’s & women’s rugby Sevens. (GB7s), ActiveOps will serve as the Official Analytics Partner for GB7s for the remainder of the 2023-2024 season including the tournaments leading up to the 2024 Paris Olympics and all of 2024-2025 season across eight locations worldwide.

 
The SaaS company, with Decision Intelligence at its core, will provide invaluable support to enhance the team’s performance, outreach and overall presence in the global sports community.
“We are delighted to welcome ActiveOps as a partner to GB7s,” said Joe Lydon, Performance Director at GB7s. “ActiveOps’ commitment to delivering operational excellence based on data-driven decision intelligence aligns seamlessly with our dedication to achieving success on and off the rugby field. This represents a powerful partnership that will help us create and better support a Data Pathway for future GB7s rugby talent and undoubtedly elevate our teams to new heights.”
Richard Jeffery. Chief Executive Officer, ActiveOps, added: “We are thrilled to announce our partnership with GB7s. We are joining forces with a team that embodies the values of excellence, teamwork, and dedication. The synergies with ActiveOps are clear given that GB7s bases its own team performances on extensive sports analytics which provides the teams with valuable information to make data-driven decisions to improve performance.”
For more information, visit www.activeops.com/gb7
Notes to editors
About HSBC SVNS
The SVNS, known as the HSBC SVNS for sponsorship reasons, is an annual series of international rugby sevens tournaments run by World Rugby featuring national sevens teams. Organised for the first time in the 1999–2000 season as the IRB World Sevens Series, the competition was formed to promote an elite-level of international rugby sevens and develop the game into a viable commercial product. The competition has been sponsored by banking group HSBC since 2014.
About GB Rugby SVNS
The Great Britain men’s and women’s national rugby sevens team are the international rugby 7s team that is the representative team of Great Britain. The team competes in the annual World Rugby Sevens Series as well as the Olympic Games and European Games. Historically, Great Britain was represented in rugby 7s by England, Scotland and Wales but the inclusion of Rugby 7s at the Olympic and European Games, together with funding issues has resulted in the formation of a permanent combined team from 2023.
About ActiveOps
At ActiveOps, we believe the ability to make every decision – the right decision, at the right time, will transform operations. Our blend of AI and human intelligence delivers the most complete and useful set of predictive and prescriptive insight to help service operations make better decisions – faster.
Service Operations has been in our DNA for 20 years. Our AI-powered SaaS solutions are underpinned by 15+ years of operational data and our AOM methodology that’s proven to drive cross department decision-making. We call this Decision Intelligence for Service Operations – and we are dedicated to the needs of banking, insurance, BPS and healthcare organisations, globally.
To find out more, visit www.activeops.com
Photo – https://mma.prnewswire.com/media/2426026/ActiveOps_1.jpg

View original content:https://www.prnewswire.co.uk/news-releases/activeops-becomes-official-analytics-partner-to-great-britain-7s-rugby-team-302159479.html

Continue Reading

Artificial Intelligence

The Lancet Publishes Results from World’s Largest Coronary CT Registry Showing New AI Technology Can Predict Cardiac Events Due to Coronary Inflammation At Least 10 Years in Advance

Published

on

the-lancet-publishes-results-from-world’s-largest-coronary-ct-registry-showing-new-ai-technology-can-predict-cardiac-events-due-to-coronary-inflammation-at-least-10-years-in-advance

OXFORD, England, May 30, 2024 /PRNewswire/ — Caristo Diagnostics Limited, a global leader in cardiovascular disease diagnostics and risk prediction, announced the results of a landmark clinical study published in The Lancet that support the ability of Caristo’s CaRi-Heart® AI technology to quantify coronary artery inflammation and accurately predict cardiac events.

This landmark study, titled “Inflammatory risk and cardiovascular events in patients without obstructive coronary artery disease: the ORFAN multicentre, longitudinal cohort study,” analysed results from the first 40,000 patients enrolled in the “ORFAN” registry, the world’s largest study that evaluates coronary computed tomography angiography (CCTA) imaging biomarkers in predicting long-term cardiovascular outcomes.
Key study findings include:
Among patients undergoing CCTA, more than 80% did not have obstructive coronary artery disease (CAD) at the time of imaging, but twice as many fatal and non-fatal cardiac events occurred in that groupCoronary inflammation, as measured by Caristo’s CaRi-Heart FAI-ScoreTM, predicted fatal and non-fatal cardiac events (including heart attack and new heart failure), independently from traditional risk factors, routine clinical CCTA interpretation, calcium scoring and plaque quantification, at least 10 years in advanceEven among the 50% of patients who had no or minimal coronary plaque at the time of the initial CCTA, those with the most abnormal FAI-Score results experienced a 9.5-fold higher risk for cardiac mortality and 5.5-fold higher risk for major adverse cardiac events (MACE)Caristo’s AI-Risk model, CaRi-Heart Risk Score, outperformed other scores in routine clinical use for prediction of cardiac mortality, and when presented to clinicians, resulted in changes of management decision in 45% of the patients. Most changes were due to clinicians’ decision to target the previously undetected coronary inflammation.”The ORFAN study is an expanding global registry which will include long-term clinical and outcome data for 250,000 patients from around the world, and we are very pleased to publish these initial results,” said Keith Channon, MD, Professor of Cardiovascular Medicine at the University of Oxford, Caristo’s Chief Medical Officer, and co-author of The Lancet publication. “Coronary inflammation is a crucial piece of the puzzle in predicting heart attack risk. We are excited to discover that CaRi-Heart results performed exceptionally well in predicting patient cardiac events. This tool is well positioned to help clinicians identify high-risk patients with seemingly ‘normal’ CCTA scans.”
Ron Blankstein, MD, Professor of Medicine and Radiology at Harvard Medical School, Director of Cardiac Computed Tomography at Brigham and Women’s Hospital, and co-author of the publication, commented: “This study, which represents one of the largest studies in the field of CCTA, has important implications for the field of preventive cardiology. I am excited about the potential of the FAI-Score biomarker, which has promising prognostic value beyond existing CT-based methods such as plaque, calcium scoring, and CAD-RADS based interpretation.”  
The study underlines the need for a robust risk prediction tool that can identify vulnerable patients with inflamed coronary arteries, particularly in those without obstructive CAD. This approach would transform CCTA from a test used to triage a minority of patients for further intervention into a prevention tool that guides management for all patients undergoing CCTA.
SCCT Webinar to Feature Study Co-Authors on June 27:
On June 27 at 11am EDT, the Society of Cardiovascular Computed Tomography (SCCT) will host a webinar on The Lancet publication findings to be presented by the lead author, Prof. Charalambos Antoniades, and joined by several co-authors (Prof. Channon, Prof. Stefan Neubauer, Prof. Ed Nicol, Prof. Blankstein and Prof. Milind Desai). The webinar will present the key results from The Lancet publication along with a panel discussion on the implications of this landmark study. Check www.caristo.com in early June for the webinar registration link.
Caristo’s patented CaRi-Heart technology marks a scientific breakthrough that is radically transforming the traditional approach to heart disease prediction, prevention and management. The technology applies advanced AI algorithms to routine coronary computed tomography angiography (CCTA) scans to visualize and quantify coronary inflammation, the otherwise invisible disease mechanism responsible for many fatal heart attacks and strokes. Prior to this publication by The Lancet, earlier validation results showing CaRi-Heart technology’s ability to aid the prediction of heart attacks were published in leading medical journals including the Lancet, JACC, European Heart Journal, and Cardiovascular Research.
The CaRi-Heart® technology is in clinical use in the UK, European Union, and Australia.
About Caristo Diagnostics Limited
Caristo Diagnostics is a global leader in cardiac and vascular disease diagnostics and risk prediction. Founded in 2018 as a spin-out company from the University of Oxford, the world’s #1 research university, Caristo has developed a portfolio of imaging-based and AI-assisted platforms that can be applied to aid the prediction and diagnosis of heart attack, stroke, and diabetes. Caristo has been recognized by Newsweek as one of the best digital health companies, and highlighted by Nature as one of the most exciting science-based companies to have emerged from academic labs. Find Caristo online on its website, LinkedIn and X.
Logo: https://mma.prnewswire.com/media/2054669/4734272/Caristo_Logo.jpg
ContactFrank Cheng, Caristo Diagnostics [email protected]

View original content:https://www.prnewswire.co.uk/news-releases/the-lancet-publishes-results-from-worlds-largest-coronary-ct-registry-showing-new-ai-technology-can-predict-cardiac-events-due-to-coronary-inflammation-at-least-10-years-in-advance-302159435.html

Continue Reading

Artificial Intelligence

ZEISS announces OCT technology enhancements to better support growing era of data-driven patient care

Published

on

zeiss-announces-oct-technology-enhancements-to-better-support-growing-era-of-data-driven-patient-care

ZEISS Medical Ecosystem fortifies the CIRRUS 6000 with the U.S. market’s largest OCT reference database and advanced cybersecurity features.
DUBLIN, Calif., May 30, 2024 /PRNewswire/ — ZEISS Medical Technology announced today that the CIRRUS® 6000 from ZEISS now enables a highly efficient and data-driven workflow for ophthalmologists, supported by the largest OCT (optical coherence tomography) reference database in the U.S. market, as well as newly enhanced cybersecurity features. As part of the ZEISS Medical Ecosystem, the latest OCT device from ZEISS, which recently received clearance by the U.S. Food and Drug Administration (FDA), helps support informed, data-driven patient care decisions across ophthalmic workflows from disease diagnosis to treatment and ongoing management.

Proven Analytics: As the largest reference database across all OCT devices in the U.S. market today, the ZEISS CIRRUS 6000 reference database now offers a comprehensive library of 870 healthy eyes, more than tripling the previous versions, with greater diversity, taking into account different optic disc sizes in addition to age. Elevating the standard of care for patients, the expanded reference database is a useful tool to facilitate individualized approaches to diagnoses and ocular health and disease management.
“ZEISS continues to forge the way toward a future of more personalized care by pioneering state-of-the-art digital workflow innovations that are proven to increase efficiencies and improve patient outcomes,” 1 says Euan S. Thomson, Ph.D., President of Ophthalmology Strategic Business Unit and Head of the Digital Business Unit for ZEISS Medical Technology. “Our expansive CIRRUS 6000 reference database provides greater data-driven insights to ophthalmologists.”
Performance: The ZEISS CIRRUS 6000 OCT provides high-speed imaging with high-definition detail, a wider field of view, enhanced visualization with AngioPlex® OCT Angiography, and clinically validated applications for retina, glaucoma, and anterior segment – all supporting more insights into a patient’s condition in less time with improved security to meet clinical compliance needs.
Patient-First Design: The CIRRUS 6000 offers enhanced security and seamless transfer of patient data from previous generations of CIRRUS for continuity of patient care. Designed to meet evolving clinical compliance and security needs, new cybersecurity features protect against cyber threats, offer advanced data security and instant disaster recovery, provide enhanced password security, enterprise-scale security requirements, and more.
”ZEISS is highly committed to improving patient care and is proud to enhance the CIRRUS OCT brand with digital tools that help keep clinics efficient and compliant. The CIRRUS 6000 enables optimized, data-driven diagnoses and empowers clinicians to manage complex ophthalmic conditions with confidence,” says Anuj Kalra, Head of Chronic Disease Management at ZEISS Medical Technology.
Learn more about the enhanced CIRRUS® 6000 from ZEISS at www.zeiss.com/cirrus6000.
1 https://www.dovepress.com/getfile.php?fileID=95911
Contact for investorsSebastian FrericksDirector Investor RelationsCarl Zeiss Meditec AGPhone: +49 3641 220 116Mail: [email protected]
Contact for the pressFrank SmithHead of Global Communications Ophthalmic DevicesCarl Zeiss Meditec Inc.Phone: +49 3641 220 331Mail: [email protected]
www.zeiss.com/newsroom
Brief Profile
Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 4,823 employees worldwide, the Group generated revenue of €2,089.3m in fiscal year 2022/23 (to 30 September).
The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company’s presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG’s shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.
For further information visit: www.zeiss.com/med
Photo – https://mma.prnewswire.com/media/2425218/ZEISS_CIRRUS_6000_OCT.jpgLogo – https://mma.prnewswire.com/media/546786/ZEISS_v1_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/zeiss-announces-oct-technology-enhancements-to-better-support-growing-era-of-data-driven-patient-care-302158900.html

Continue Reading

Trending